Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality

被引:420
作者
Osuchowski, Marcin F.
Welch, Kathy
Siddiqui, Javed
Remick, Daniel G.
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA
关键词
D O I
10.4049/jimmunol.177.3.1967
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mortality in sepsis remains unacceptably high and attempts to modulate the inflammatory response failed to improve survival. Previous reports postulated that the sepsis-triggered immunological cascade is multimodal: initial systemic inflammatory response syndrome (SIRS; excessive pro-, but no/low anti-inflammatory plasma mediators), intermediate homeostasis with a mixed anti-inflammatory response syndrome (MARS; both pro- and anti-inflammatory mediators) and final compensatory anti-inflammatory response syndrome (CARS; excessive anti-, but no/low proinflammatory mediators). To verify this, we examined the evolution of the inflammatory response during the early phase of murine sepsis by repetitive blood sampling of septic animals. Increased plasma concentrations of proinflammatory (IL-6, TNF, IL-1 beta, KC, MIP-2, MCP-1, and eotaxin) and anti-inflaminatory (TNF soluble receptors, IL-10, IL-1 receptor antagonist) cytokines were observed in early deaths (days 1-5). These elevations occurred simultaneously for both the pro- and anti-inflammatory mediators. Plasma levels of IL-6 (26 ng/ml), TNF-alpha (12 ng/ml), KC (33 ng/ml), MIP-2 (14 ng/ml), IL-1 receptor antagonist (65 ng/ml), TNF soluble receptor 1 (3 ng/ml), and TNF soluble receptor 11 (14 ng/ml) accurately predicted mortality within 24 h. In contrast, these parameters were not elevated in either the late-deaths (day 6-28) or survivors. Surprisingly, either pro- or anti-inflammatory cytokines were also reliable in predicting mortality up to 48 h before outcome. These data demonstrate that the initial inflammatory response directly correlates to early but not late sepsis mortality. This multifaceted response questions the use of a simple proinflammatory cytokine measurement for classifying the inflammatory status during sepsis.
引用
收藏
页码:1967 / 1974
页数:8
相关论文
共 59 条
[1]   Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients [J].
Abraham, E ;
Laterre, PF ;
Garbino, J ;
Pingleton, S ;
Butler, T ;
Dugernier, T ;
Margolis, B ;
Kudsk, K ;
Zimmerli, W ;
Anderson, P ;
Reynaert, M ;
Lew, D ;
Lesslauer, W ;
Passe, S ;
Cooper, P ;
Burdeska, A ;
Modi, M ;
Leighton, A ;
Salgo, M ;
Van der Auwera, P .
CRITICAL CARE MEDICINE, 2001, 29 (03) :503-510
[2]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[3]   Anti-inflammatory response is associated with mortality and severity of infection in sepsis [J].
Ashare, A ;
Powers, LS ;
Butler, NS ;
Doerschug, KC ;
Monick, MM ;
Hunninghake, GW .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2005, 288 (04) :L633-L640
[4]  
Ayala A, 1997, J TRAUMA, V42, P882, DOI 10.1097/00005373-199705000-00019
[5]   Is sepsis-induced apoptosis associated with macrophage dysfunction? [J].
Ayala, A ;
Urbanich, MA ;
Herdon, CD ;
Chaudry, IH .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1996, 40 (04) :568-574
[6]   POLYMICROBIAL SEPSIS BUT NOT LOW-DOSE ENDOTOXIN INFUSION CAUSES DECREASED SPLENOCYTE IL-2/IFN-GAMMA RELEASE WHILE INCREASING IL-4/IL-10 PRODUCTION [J].
AYALA, A ;
DEOL, ZK ;
LEHMAN, DL ;
HERDON, CD ;
CHAUDRY, IH .
JOURNAL OF SURGICAL RESEARCH, 1994, 56 (06) :579-585
[7]   PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN [J].
BEUTLER, B ;
MILSARK, IW ;
CERAMI, AC .
SCIENCE, 1985, 229 (4716) :869-871
[8]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[9]   Sir Isaac Newton, sepsis, SIRS, and CARS [J].
Bone, RC .
CRITICAL CARE MEDICINE, 1996, 24 (07) :1125-1128
[10]  
Bonville Daniel A, 2004, Surg Infect (Larchmt), V5, P39, DOI 10.1089/109629604773860291